🇺🇸 FDA
Pipeline program

SRP-1005

SRP-1005-101

Phase 1 small_molecule active

Quick answer

SRP-1005 for Huntington's Disease is a Phase 1 program (small_molecule) at Sarepta Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Sarepta Therapeutics
Indication
Huntington's Disease
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials